A phase two clinical trial at the University of California Center for Medicinal Cannabis Research is examining the effects of vaporized-cannabis to treat HIV-related neuropathic pain.
The study involves three different doses of vaporized cannabis that contain THC and varying concentrations of CBD.
Researchers will look at the acute effects of cannabis on: pain intensity; endocannabinoid levels in the blood; and the relationship of pain with heart rate.
A text messaging program called IMPACT will be used to monitor the association between pain relief and cannabis use.
Neuropathic pain is exceedingly difficult-to-treat because it involves the central nervous system – not pain receptors – which are typically associated with other forms of chronic pain.
The study is expected to be completed by the end of 2020.